Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma

Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis. Although sorafenib effectively prolongs median survival rates of patients wit...

Full description

Bibliographic Details
Main Authors: Zhi Zeng, Qiliang Lu, Yang Liu, Junjun Zhao, Qian Zhang, Linjun Hu, Zhan Shi, Yifeng Tu, Zunqiang Xiao, Qiuran Xu, Dongsheng Huang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.641522/full